Queisser W, Preusser P, Mross K B, Fritze D, Rieche K, Beyer J H, Achterrath W, Edler L
Onkologisches Zentrum, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim.
Onkologie. 1990 Jun;13(3):190-3. doi: 10.1159/000216756.
Eighteen patients with advanced squamous cell carcinoma of the esophagus without prior chemotherapy were treated with carboplatin. Based on experimental data a split dose of carboplatin of 130 mg/m2 given on days 1, 3 and 5 was administered. In cases showing no WBC and platelet suppression, an escalated dose of 160 mg/m2 was proposed. Out of 18 evaluable patients no complete and partial responses were observed and there were only 5 patients with stable disease (27.8%) lasting 2-7 months. Therefore, carboplatin in the regimen used shows no meaningful antitumor activity in patients with advanced esophageal carcinoma. The escalated dose (mean 107-123% of the starting dose) was well tolerated and was followed by only minor gastrointestinal and hematological toxicity. Therefore, this regimen can be recommended for future trials.
18例未经前期化疗的晚期食管鳞状细胞癌患者接受了卡铂治疗。根据实验数据，给予卡铂分剂量130mg/m²，于第1、3和5天给药。对于未出现白细胞和血小板抑制的患者，建议将剂量增至160mg/m²。在18例可评估患者中，未观察到完全缓解和部分缓解，仅有5例疾病稳定（27.8%），持续2至7个月。因此，所用方案中的卡铂在晚期食管癌患者中未显示出有意义的抗肿瘤活性。增加的剂量（平均为起始剂量的107 - 123%）耐受性良好，仅伴有轻微的胃肠道和血液学毒性。因此，该方案可推荐用于未来的试验。
